Alan Findlay Haughan

USPTO Granted Patents = 29 (Patent Applications = 4)

EPO Patents = 8 (Patent Applications = 3)

Average Co-Inventor Count = 8.0

ph-index = 6

Forward Citations = 183(Granted Patents)

Location History:

Slough, GB (2012)
Saffron Walden Essex, GB (2014 - 2015)
Cambridge, GB (1998 - 2018)
Saffron Walden, DE (2018)
Saffron Walden, GB (2013 - 2023)

Company Filing History:

13 out of 53

Chdi Foundation, Inc.

Darwin Discovery Limited

Years Active: 1998-2025

where 'Filed Patents' based on already Granted Patents

29 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12428413 - Rho kinase inhibitors and compositions and methods of use thereof (2025-09-30),

2. 12281116 - HTT modulators for treating Huntington's disease (2025-04-21),

3. 11806346 - HTT modulators for treating Huntington's disease (2023-11-07),

4. 10457675 - Histone deacetylase inhibitors and compositions and methods of use thereof (2019-10-29),

5. 10106535 - Histone deacetylase inhibitors and compositions and methods of use thereof (2018-10-23),

6. 10105363 - Histone deacetylase inhibitors and compositions and methods of use thereof (2018-10-23),

7. 10065948 - Histone deacetylase inhibitors and compositions and methods of use thereof (2018-09-04),

8. 10053434 - Histone deacetylase inhibitors and compositions and methods of use thereof (2018-08-21),

9. 10047073 - Histone deacetylase inhibitors and compositions and methods of use thereof (2018-08-14),

10. 9783488 - Histone deacetylase inhibitors and compositions and methods of use thereof (2017-10-10),

11. 9765054 - Histone deacetylase inhibitors and compositions and methods of use thereof (2017-09-19),

12. 9617259 - Histone deacetylase inhibitors and compositions and methods of use thereof (2017-04-11),

13. 9562021 - Histone deacetylase inhibitors and compositions and methods of use thereof (2017-02-07),

14. 8957090 - Fused bicyclic pyridine and pyrazine derivatives as kinase inhibitors (2015-02-17),

15. 8785628 - Triazine derivatives as kinase inhibitors (2014-07-22),

Title: Alan Findlay Haughan: Pioneering Innovations in Healthcare

Introduction: Alan Findlay Haughan is a prominent inventor based in Cambridge, GB, with an impressive track record of 27 patents to his name. His groundbreaking work in developing HTT modulators for treating Huntington's disease and histone deacetylase inhibitors has revolutionized the field of healthcare.

Latest Patents: Haughan's latest patents include HTT modulators for treating Huntington's disease, which are compounds proven to be effective in modulating the HTT protein and aiding in the treatment of Huntington's disease. Additionally, his work on histone deacetylase inhibitors has resulted in the development of compounds that show promising potential in inhibiting HDAC enzymes, opening new doors for therapeutic interventions.

Career Highlights: Throughout his career, Haughan has made significant contributions to the field of biopharmaceuticals. He has worked with renowned companies such as CHDI Foundation, Inc. and UCB Pharma S.A., where his innovative research and patent developments have had a lasting impact on the industry.

Collaborations: Haughan has collaborated closely with fellow researchers and colleagues, including Roland W Bürli and Celia Dominguez. Together, they have pooled their expertise to drive forward cutting-edge research and bring innovative solutions to the forefront of healthcare.

Conclusion: Alan Findlay Haughan's dedication to advancing healthcare through his inventions and patents is truly commendable. His pioneering work in developing treatments for Huntington's disease and histone deacetylase inhibitors reflects his unwavering commitment to making a positive impact on the lives of patients worldwide.

This text is generated by artificial intelligence and may not be accurate.